Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination

Jinyi Tang1,2,3†, Cong Zeng4,5†, Thomas M. Cox2, Chaofan Li1,2,3, Young Min Son1,6, In Su Cheon1,2,3, Yue Wu1, Supriya Behl8, Justin J. Taylor9, Rana Chakaraborty8, Aaron J. Johnson7, Dante N. Shiavo3, James P. Utz3, Janani S. Reisenauer3, David E. Midthun3, John J. Mullon3, Eric S. Edell3, Mohamad G. Alameh10, Larry Borish11, William G. Teague12, Mark H. Kaplan13, Drew Weissman10, Ryan Kern9, Haitao Hu14, Robert Vassallo3, Shan-Lu Liu4,5*, Jie Sun1,2,3,7*.

SARS-CoV-2 mRNA vaccination induces robust humoral and cellular immunity in the circulation; however, it is currently unknown whether it elicits effective immune responses in the respiratory tract, particularly against variants of concern (VOCs), including Omicron. We compared the SARS-CoV-2 S-specific total and neutralizing antibody responses, and B and T cell immunity, in the bronchoalveolar lavage fluid (BAL) and blood of COVID-19–vaccinated individuals and hospitalized patients. Vaccinated individuals had significantly lower levels of neutralizing antibody against D614G, Delta (B.1.617.2), and Omicron BA.1.1 in the BAL compared with COVID-19 convalescents despite robust S-specific antibody responses in the blood. Furthermore, mRNA vaccination induced circulating S-specific B and T cell immunity, but in contrast to COVID-19 convalescents, these responses were absent in the BAL of vaccinated individuals. Using a mouse immunization model, we demonstrated that systemic mRNA vaccination alone induced weak respiratory mucosal neutralizing antibody responses, especially against SARS-CoV-2 Omicron BA.1.1 in mice; however, a combination of systemic mRNA vaccination plus mucosal adenovirus-S immunization induced strong neutralizing antibody responses not only against the ancestral virus but also the Omicron BA.1.1 variant. Together, our study supports the contention that the current COVID-19 vaccines are highly effective against severe disease development, likely through recruiting circulating B and T cell responses during reinfection, but offer limited protection against breakthrough infection, especially by the Omicron sublineage. Hence, mucosal booster vaccination is needed to establish robust sterilizing immunity in the respiratory tract against SARS-CoV-2, including infection by the Omicron sublineage and future VOCs.

INTRODUCTION

The ongoing coronavirus disease 2019 (COVID-19) pandemic is a global public health crisis, and vaccination is considered the key to ending the pandemic (1, 2). It is well recognized that current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines, particularly mRNA-based vaccination, can induce robust humoral and cellular immunity and prevent severe disease caused by SARS-CoV-2 (3); however, protection against asymptomatic to mild infection and transmission, particularly after SARS-CoV-2 variants of concern (VOCs) exposure, by mRNA vaccination is rather limited (4, 5). The reasons for this are poorly defined.

Notably, most of the previous studies were conducted using blood to determine circulating antibodies and B and T cell immunity after vaccination (6). However, SARS-CoV-2 enters the host predominantly through the respiratory tract. As a result, respiratory mucosal antibodies and tissue-resident memory T and B cells are likely among the early responders during viral entry, and so, they are believed to be essential for the protection against the establishment of viral infection after vaccination or prior viral exposure (7). Thus, we reasoned that it was critical to characterize respiratory mucosal humoral and cellular immunity after COVID-19 mRNA vaccination or natural infection to better understand the vaccine- or infection-mediated protection against SARS-CoV-2 infection. In addition, the SARS-CoV-2 Omicron sublineage easily escapes both vaccine- and infection-elicited antibody neutralization in the blood (8–14). It is currently unclear whether efficient mucosal neutralizing antibody responses can be induced by vaccination and/or natural infection and to what extent this could protect against SARS-CoV-2 infection.

Previous studies have examined the COVID-19 mRNA vaccine-induced humoral and cellular immunity in the nasal mucosa (15, 16). However, it is still controversial whether intramuscular mRNA immunization can induce meaningful neutralizing antibodies and tissue-resident T and B cells in the nasal tissue (17, 18), potentially in part because of the limited amount of fluids/cells that can be sampled in nasal washes or nasal swabs. Thus, the current understanding of the COVID-19 vaccine–induced mucosal immunity in the respiratory tract remains largely elusive.

Here, we collected bronchoalveolar lavage fluid (BAL) and blood of unvaccinated healthy donors, COVID-19–vaccinated individuals,
RESULTS
Characterization of respiratory mucosal antibody responses after vaccination or natural infection
To determine the humoral and cellular immune responses after COVID-19 vaccination, we collected blood and BAL samples from 19 COVID-19–vaccinated individuals (Fig. 1A). Most of these individuals had received two doses of mRNA vaccination, with three individuals receiving the third booster and one having the Johnson & Johnson vaccine. The vaccine type, timing of collection, age, and sex information are included in table S1. We compared the vaccine-induced respiratory and circulating antibodies, as well as cellular immune responses, with those of hospitalized COVID-19 convalescent patients whom we had previously recruited between September 2020 and April 2021 when the D614G and Alpha variants dominated (19). We first performed enzyme-linked immunosorbent assay (ELISA) to determine and compare the SARS-CoV-2 S1 or receptor binding domain (RBD)–specific immunoglobulin G (IgG), IgA, and IgM levels in unvaccinated control (non–SARS-CoV–infected), vaccinated, and convalescent groups in the plasma. Similar to what was previously shown (3, 20), COVID-19 vaccination induced robust S1- or RBD-specific plasma IgG at levels comparable to severe cases of natural infection (Fig. 1B and fig. S1A). The S1 or RBD-specific IgG levels in the BAL were also comparable between COVID-19–vaccinated and convalescent groups (Fig. 1C and fig. S1B). Compared with unvaccinated donors, COVID-19 convalescents exhibited moderate but detectable S1-specific IgA responses in the blood (Fig. 1D and fig. S1C). Importantly, prior severe SARS-CoV-2 infection provoked significant levels of S1 or RBD-specific IgA in the respiratory mucosa, which was not the case for COVID-19 vaccination (Fig. 1E and fig. S1D). The lack of notable IgA production in the respiratory mucosal appeared to contrast with the detection of moderate but significant IgA responses in the saliva after mRNA vaccination (21, 22). We also examined IgM in the blood and BAL and observed that, whereas detectable levels of IgM were present in the circulation of both the COVID-19–vaccinated group and prior infection cases, only prior infection elicited significantly elevated IgM responses in the BAL (fig. S1, E to H).

Given the existence of cross-reactive and neutralizing antibodies against non-S1 or RBD epitopes (23–25), we further examined binding antibody response against Spike protein and nucleocapsid protein, which would have informed potential unidentified infection. COVID-19 convalescents showed significantly higher S-specific IgG, IgA, and N-specific IgG, but not S-specific IgM levels in blood, compared with those of vaccinated individuals (fig. S1, I to L). Similar results were found in the BAL (fig. S1, M to P). Importantly, and consistent with results of S1 or RBD-specific IgA, a significant level of S-specific

---

Fig. 1. Systemic and respiratory antibody responses in COVID-19 convalescents and vaccinated individuals. (A) Schematic of recruited cohorts (n=5 for unvaccinated donors, n=19 for vaccinated individuals, and n=10 for COVID-19 hospitalized convalescents) and experimental procedures. Figures were created with BioRender. (B to E) Levels of SARS-CoV-2 S1 or RBD binding IgG (B and C) or IgA (D and E) in plasma and BAL fluid of unvaccinated donors (n=5), COVID-19–vaccinated individuals (n=19), or convalescents (n=10). One individual receiving Johnson & Johnson is indicated as pink in the vaccinated group. Three individuals receiving the booster (BNT162b2 or mRNA-1273) are indicated as orange in the vaccinated group. Enrolled donors’ demographics are provided in table S1 or the previous publication (19). Data in (B) to (E) are means ± SEM. Statistical differences were determined by one-way ANOVA, and P values are indicated by ns, not significant (P > 0.05); *P < 0.05; **P < 0.01; ***P < 0.001; and ****P < 0.0001.

---

Tang et al., Sci. Immunol. 7, eadd4853 (2022)  21 October 2022 2 of 10
IgA was observed in both BAL and blood from convalescents but not vaccinated individuals (Fig. S1, M to O). Together, these results revealed that, in contrast to natural infection, COVID-19 vaccination did not provoke robust IgA responses in the respiratory tract in our cohort.

**Mucosal antibody neutralizing activity against VOCs**

The humoral protection against SARS-CoV-2 infection relies on the induction of robust neutralizing antibody (26, 27). We thus examined the plasma-neutralizing antibody activity against SARS-CoV-2 D614G, Delta, and Omicron BA.1.1 Spike-pseudotyped lentiviruses. Whereas COVID-19–vaccinated and convalescent individuals exhibited comparable high levels of circulating neutralizing antibody responses against all VOCs, the Delta and Omicron BA.1.1 variants exhibited more than 2- and 10-fold decrease in end point of 50% reduction of virus expression, respectively, compared with D614G (Fig. 2, A to C, and fig. S2, A to E), consistent with recent results showing that VOCs, especially Omicron sublineage, have significant immune evasion capability (8–14, 28–30).

We next compared neutralizing antibody responses in BAL of COVID-19–vaccinated and convalescent groups along with healthy controls. Despite the overall lower neutralizing antibody levels in BAL compared with that in the blood, the convalescent group showed ~3-fold higher neutralizing antibody activity than the vaccinated group, especially for the ancestral D614G (P < 0.05) and the Delta variant (P < 0.01) (Fig. 2, D and E, and fig. S2, F and G). The titers for the Omicron BA.1.1 variants were mostly below the level of detection in the BAL (Fig. 2F and fig. S2H), reflecting the stronger escape of Omicron BA.1.1 from BAL neutralizing antibodies (fig. S2, I and J). Of note, one of three who had received a third booster vaccination exhibited an above-the-threshold yet low level of neutralization activity against Omicron BA.1.1 (Fig. 2F and fig. S2I), suggesting that a third booster vaccine may offer some, but limited, levels of protection. Overall, these results indicated that natural infection elicited stronger humoral immunity in mucosal surface compared with mRNA vaccination in our cohorts.

**Mucosal cellular immunity after vaccination or natural infection**

Although memory T and B cells do not confer sterilizing immunity, they are important in constraining viral dissemination and protecting against severe diseases once a virus breaches neutralizing humoral immunity (31–34). Both circulating and tissue-resident memory T and B cells are believed to provide disease protection against severe respiratory viral infection (35–38). We therefore examined systemic and tissue-resident memory T and B cell responses after mRNA vaccination or natural infection. Compared with unvaccinated controls, vaccinated individuals had higher RBD-specific B cells in the

---

**Fig. 2. COVID-19–vaccinated individuals exhibit lower respiratory neutralizing antibody responses compared with convalescents.** Plasma and BAL neutralizing activity in unvaccinated donors and vaccinated and convalescent individuals. (A to C) Neutralizing antibody titers (NT_{50}) in plasma against SARS-CoV-2 S D614G (A), Delta (B), and Omicron BA.1.1 (C) pseudotyped virus in unvaccinated donors (n = 5) and vaccinated (n = 17) and convalescent (n = 10) individuals. HEK293T-ACE2 cells were used as targeted cells for infection. (D to F) Neutralizing antibody titers (NT_{50}) in BAL against SARS-CoV-2 S D614G (D), Delta (E), and Omicron BA.1.1 (F) pseudotyped virus in unvaccinated donor (n = 5) and vaccinated (n = 17) and convalescent individuals (n = 10). One individual receiving Johnson & Johnson is indicated as pink in the vaccinated group. Three individuals receiving the booster shot (BNT162b2 or mRNA-1273) are indicated as orange in the vaccinated group. nAb, neutralizing antibody; LOD, limit of detection. Data are means ± SEM. Statistical differences were determined by one-way ANOVA, and P values are indicated by ns, not significant (P > 0.05); *P < 0.05; **P < 0.01; ***P < 0.001; and ****P < 0.0001.
blood (Fig. S3, A to D). Notably, RBD-specific B cells were markedly lower in BAL compared with those of peripheral blood mononuclear cells (PBMCs) (Fig. 3A and fig. S3E). As reported before (38, 39), vaccination induced notable S-specific tumor necrosis factor (TNF)– or interferon-γ (IFN-γ)–producing CD8⁺ or CD4⁺ T cells in the circulation but failed to elicit strong S-specific cytokine-producing CD8⁺ or CD4⁺ T cell responses in the BAL (Fig. 3, B and C, and fig. S4). In contrast, convalescent BAL exhibited much higher RBD-specific B cells compared with the paired blood samples (Fig. 3D), suggesting that vaccination does not induce tissue-residing memory B cell responses as effectively as natural infection. Further, BAL from COVID-19 convalescents had higher cytokine-producing CD8⁺ and CD4⁺ T cells than blood (Fig. 3, A and B), although paired analysis was not performed here owing to the availability of the samples obtained from a previous study (19). Within the total CD8⁺ or CD4⁺ T cell compartments, the levels of most memory T cell subsets in the blood and/or BAL were quite similar between unvaccinated or vaccinated individuals, except the blood central memory T cell population (fig. S4). Thus, unlike SARS-CoV-2 natural infection, mRNA vaccination did not appear to induce significant SARS-CoV-2–specific B and T cell memory in the respiratory mucosa in contrast to that in the blood in our cohorts.

**Fig. 3. COVID-19-vaccinated individuals exhibit systemic cellular immunity not evident in the respiratory tract.** (A) Frequency of SARS-CoV-2 RBD-specific B cells in the blood (PBMC) and the BAL of vaccinated individuals (n = 14). (B and C) Frequencies of TNF- and IFN-γ–producing CD8⁺ (B) or CD4⁺ (C) T cells in the blood (PBMC) and the BAL of vaccinated individuals (n = 13) after S peptide pool stimulation. (D) Frequency of SARS-CoV-2 RBD-specific B cells in the blood (PBMC) and the BAL of convalescent individuals (n = 8). (E and F) Frequencies of TNF- and IFN-γ–producing CD8⁺ (E) or CD4⁺ (F) T cells in the blood (PBMC) and the BAL of convalescents (n = 5) after S peptide pool stimulation. Data are means ± SEM. Numbers below the graph show ratio of positive staining within total samples. Statistical differences were determined by paired t test in (A) to (D) and independent t test in (E) and (F). P values are indicated by ns, not significant (P > 0.05); *P < 0.05; **P < 0.01; and ***P < 0.001.

mRNA plus mucosal Ad5-S vaccination induces strong neutralizing immunity against Omicron BA.1.1

Given the suboptimal mucosal immunity induced by the current COVID-19 mRNA vaccination, we used a mouse model to identify potential strategies that promote and/or amplify mucosal humoral and cellular immunity after mRNA vaccination. To this end, we immunized wild-type C57BL/6 mice with phosphate-buffered saline (PBS), two doses of mRNA-encoding codon-optimized S (mRNA-S), three doses of mRNA-S, two doses of mRNA-S plus an intranasal immunization of S protein trimer with adjuvant [STING (stimulator of interferon genes) ligand, cGAMP (cyclic guanosine monophosphate–adenosine monophosphate) (40)], or two doses of mRNA-S plus an intranasal of adenovirus type 5 encoding S protein (Ad5-S) (Fig. 4A). We focused on intranasal immunization in mRNA-immunized mice, in keeping the contention that induction of mucosal immunity likely occurs in previously vaccinated individuals who will be willing to receive mucosal booster vaccines. mRNA plus Ad5-S vaccination induced greatly increased BAL RBD-specific B cells (Fig. 4B). Furthermore, mRNA plus Ad5-S vaccination induced potent mucosal CD8⁺ and CD4⁺ T cell responses but not in the spleen, whereas mRNA plus cGAMP/S trimer immunization led to robust CD4⁺ T cell responses in the spleen (Fig. 4C and fig. S5). mRNA immunization, with or without the third dose of mucosal immunization, induced strong circulating S1 or RBD-specific IgG in the blood and the BAL (Fig. 4D and fig. S6A). A third dose of mucosal immunization of S protein, with S trimer plus cGAMP or Ad5-S, resulted in significant increases of both S1- and RBD-specific IgA in the BAL (Fig. 4E), with Ad5-S inducing the highest RBD-specific IgA in the respiratory mucosa (Fig. 4E). Ad5-S also generated significantly higher levels of plasma IgA, IgM, and BAL IgM than other groups (fig. S6, B to D).

All immunized groups showed strong neutralization against D614G and the Delta variant in the plasma, although three-dose mRNA or two-dose mRNA plus Ad5-S vaccination induced higher levels of neutralizing antibody compared with two doses of mRNA immunization (fig. S6, E and F). As would be expected, the mouse plasma neutralization activities against Omicron BA.1.1 were also dramatically reduced relative to D614G or Delta (fig. S6G), indicating that Omicron BA.1.1 is capable of escaping immunization-induced neutralizing antibody
responses in the mouse blood similar to those in humans. However, we were still able to detect neutralizing antibody activities, at approximately similar levels, against the Omicron BA.1.1 variant in all immunized groups (fig. S6G).

The neutralizing antibody activity in the BAL of mRNA-immunized mice (two or three doses) was generally lower than that in the blood but clearly detectable against D614G, with a ~4-fold reduction in Delta, yet was around the limit of detection for the Omicron BA.1.1 variant (Figs. 4, F to H). mRNA plus Ad5-S significantly increased the neutralization titer against the ancestral D614G by approximately 3 logs compared with other vaccination groups and, more importantly, maintained the strong neutralization activity against Delta as well as the Omicron BA.1.1 variant (Fig. 4, F to H).

To confirm that the IgA response is induced by boosting the primed response, we immunized wild-type C57BL/6 mice with PBS, Ad5-S alone, or one-dose mRNA-S plus Ad5-S. The S1- or RBD-specific IgA levels were generally higher in plasma from mRNA-S plus Ad5-S immunization compared with those of Ad5-S immunization alone (fig. S7A). Of note, mRNA plus Ad5-S immunization induced dramatically higher S1- or RBD-specific IgA levels in the BAL, but not in nasal washes, compared with those of Ad5-S immunization alone (fig. S7, B and C). Furthermore, S1- or RBD-specific IgG and IgM levels were higher in plasma, BAL, and nasal wash after mRNA-S plus Ad5-S immunization compared with those of Ad5-S immunization alone (fig. S7, D to I). In addition, mRNA-S plus Ad5-S immunization induced strong antigen-specific T cell responses, particularly in the BAL (fig. S7, J to N). Intranasal vaccination of anesthetized mice inadvertently introduces vaccine material into lower lungs (41); however, Ad5-S intranasal immunization did not appear to induce notable weight loss and provoked relatively moderate inflammatory responses in the lung compared with those of influenza infection (fig. S8), suggesting that mucosal adenovirus delivery does not seem to lead to significant host morbidity or overt lung pathology.

Together, these data indicated that compared with the systemic mRNA booster, the mucosal Ad5-S booster immunization elicits broadened antibody neutralization in the BAL against VOCs. Thus, we...
have here identified a promising immunization strategy that can induce potent mucosal neutralizing antibody effectively against the Omicron BA.1.1 variant (fig. S9).

DISCUSSION
COVID-19 mRNA vaccination elicited at least comparable neutralizing antibody levels to COVID-19 convalescents in the circulation but generated considerably lower mucosal IgA and neutralizing antibody responses against SARS-CoV-2 D614G, Delta, and Omicron BA.1.1 variants than those of convalescents, indicating that the overall magnitude of mucosal antibody responses is suboptimal after vaccination. Consistent with the idea, several recent large clinical studies have revealed that mRNA vaccination is relatively less efficient in the protection against infection compared with prior natural infection during the Delta wave (42–44). Of note, the Omicron BA.1.1 variant almost completely escaped the neutralization activity of BAL from either vaccinated or previously infected individuals. In addition, we provide compelling real-world evidence that mRNA vaccination does not induce notable lung tissue-residing S-specific memory B and T cells. Thus, despite the induction of robust circulating humoral and cellular immunity, current COVID-19 mRNA vaccines likely do not provoke sufficient levels of mucosal immunity in the human lower respiratory tract that would be needed for immediate clearance of the infectious Omicron BA.1.1 variant to prevent the establishment of infection. Such a notion is consistent with the fact that the Omicron sublineage continues to spread at a rapid pace in regions with high rates of vaccination and/or prior natural infection.

Our data do not dispute the notion that current vaccines are highly effective in preventing hospitalization and death. The prevention of severe disease after infection is conferred mainly by memory T and B cells (38, 45). To this end, CD8 T cell epitopes within Omicron Spike protein remain conserved to those of ancestral strains (46–48). Thus, even though Omicron is able to breach the defense of mucosal neutralizing antibody to cause infection, the recruitment of vaccine-induced circulating memory T cells during SARS-CoV-2 breakthrough infection enables protection that restrains further viral dissemination, preventing severe disease development after infection. Nevertheless, these data suggest that mucosal humoral immunity is particularly vulnerable to immune escape by Omicron BA.1.1 and other sublineage. It is thus quite likely that the current vaccine strategy, even with further boosters, will not achieve “herd immunity” or prevent the occurrence of new infections or reinfections with future VOCs, particularly those with immune-evasive properties such as the Omicron sublineage. Thus, our findings have significant public health implications.

Our data suggest that a mucosal SARS-CoV-2 booster vaccine may be necessary to achieve more robust immunity and protection from reinfection by future variants. To this end, we have provided a proof-of-principle experiment that systemic mRNA plus mucosal Ad5-S vaccination provoked strong cellular immunity in the respiratory tract and compelling mucosal IgA and neutralizing activity against Omicron BA.1.1. Mucosal adenovirus delivery has concerns of safety and applicability on a large scale. However, an Ad5-S–based mucosal booster strategy in vaccinated individuals has been found to be safe and induced stronger plasma antibody responses (49). Thus, an adenoviral booster vaccine potentially has great translational and clinical relevance. Alternatively, emerging novel vaccine platforms such as virus-like nanoparticles (50), which can provide strong adjuvant activity and prolonged antigen presentation in vivo, may also be a promising approach to boost mucosal neutralizing immunity against Omicron or future VOCs.

Compared with convalescents, BAL from vaccinated individuals had reduced neutralizing activities despite similar levels of S1- or RBD-specific IgG present in the two groups. Further, BAL from mice immunized with mRNA alone or mRNA plus S-trimer had comparable RBD-specific IgG levels to those of mRNA plus Ad5–S–immunized mice, with the latter showing markedly higher neutralizing activities against SARS-CoV-2 ancestral virus or VOCs, indicating that BAL IgG levels alone do not perfectly correlate with the levels of neutralizing activity. Whether this is due to the strong RBD-specific IgA responses present in the respiratory mucosa after natural infection or mucosal Ad5-S booster immunization is currently unknown. Of note, prior studies have identified that viral infection can lead to persistent germinal center reaction and antibody production in the lung (51, 52). Therefore, local antigen–specific IgG or IgA produced in situ in the respiratory tract after viral infection may provide better neutralizing activities than those diffused solely from the blood after systemic immunization. In addition, persistent damage, inflammation, or chronic antigen deposition in the lung may further facilitate the development of local neutralizing antibody responses after natural infection.

Our study has several limitations. Because of the highly invasive nature of the BAL procedure, we were not able to recruit a large cohort of study participants. Furthermore, the study procedure made it challenging to time recruitment or perform a longitudinal analysis; rather, it enabled a snapshot of vaccination- or infection-induced mucosal immunity. In addition, most of the participants were older and may not be representative of the entire vaccinated population, although this age group is considered as the primary targeting population for vaccination because they are at highest risk of infection associated with mortality and complications. Last, soluble Spike trimers engaging angiotensin-converting enzyme 2 (ACE2) may trigger undesirable side effects after immunization of adenovirus–vectored vaccine (53); thus, using Spike harboring mutations known to abolish high-affinity interactions with human ACE2 shall be considered for future vaccine design.

Nevertheless, we have provided critical evidence detailing the mucosal humoral and cellular immunity after vaccination in the respiratory tract. Our study highlights the importance of focusing on vaccine-induced mucosal immunity (54) and argues for the necessity of a mucosal booster strategy in addition to the current approach of intramuscular COVID-19 vaccines.

MATERIALS AND METHODS
Study design
The goal of the study was to identify the respiratory mucosal immune response after COVID-19 vaccination. We recruited a cohort of unvaccinated healthy individuals (n = 5) and COVID-19–vaccinated individuals (n = 19), most of whom received mRNA vaccination, as well as convalescents (n = 10) who recovered from acute COVID-19 for 2 to 3 months. We obtained blood samples and BAL fluid from the study subjects. ELISA and viral neutralization assay were performed to determine SARS-CoV-2–specific binding and neutralizing antibodies in the circulation or in the respiratory tract. Spectral flow cytometry was performed with PBMCs and BAL cells for the
characterization of circulating and respiratory adaptive immune cell responses in this cohort. Last, we used an animal immunization model for the development of an intranasal booster strategy that can induce robust mucosal immune response in the respiratory tract, particularly against SARS-CoV-2 VOCs.

**Study cohorts**

BAL or blood samples were collected from unvaccinated donors, COVID-19–vaccinated individuals, or COVID-19 convalescents at Mayo Clinic under protocols approved by Mayo Clinic Institutional Review Boards (protocol ID 19-012187). Study participants included nonpregnant adults who were undergoing flexible bronchoscopy as part of their clinical management. However, participants who had presence of hereditary respiratory diseases (such as cystic fibrosis), a clinical history of primary aspiration, neuromuscular problems, primary or secondary immune deficiencies, invasive viral or bacterial infections, or a cancer diagnosis were excluded in the study. Informed consent for the use of BAL, blood, and their derivatives for research was obtained from all enrolled individuals. For COVID-19 convalescents, three unvaccinated and three vaccinated samples were from a cohort that was previously recruited (19). Most of the vaccinated subjects received two doses of Pfizer/bioNTech (BNT162b2) or Moderna (mRNA-1273) mRNA vaccination, with three individuals receiving the third booster vaccination and one individual having the Johnson & Johnson (Ad26.COV2.S) vaccination. All vaccinated samples were obtained within 8 months after vaccination. Full cohort and demographic information are provided in table S1.

**BAL collection**

Fiberoptic bronchoscopy and BAL were performed using moderate conscious sedation using standard clinical procedural guidelines in an outpatient bronchoscopy suite. Conscious sedation was administered in accordance with hospital policies, and a suitably trained registered nurse provided monitoring throughout the procedure. The bronchoscope was wedged (tip of the scope placed securely) in an airway leading to a segment of the lung. About 100 to 200 ml of saline was instilled in 20-ml aliquots until 60 ml of lavage fluid was obtained. The specimen was placed on ice and immediately hand-carried to laboratory for analysis. The fluid collected was placed on ice and transferred immediately to the laboratory for processing.

**Human single-cell purification**

Plasma was isolated from whole blood by centrifuging at 1600 rpm, room temperature (RT), for 10 min. Plasma was collected and inactivated for 30 min at 56°C and then stored at −80°C for ELISA and neutralization assay. After plasma isolation, leftover blood was mixed with PBS and then gently put over on Ficoll-Paque (Cytiva, 17144002) in a 15-ml tube. Buffy coat generated by centrifuging at 400g for 30 min at RT was collected. For single-cell purification from BAL, BAL was filtered with a 70-μm cell strainer (Falcon) and then centrifuged at 350g for 6 min at 4°C. Supernatant was collected, and aliquots were stored at −80°C for ELISA and neutralization assay. Supernatant of BAL was further concentrated for 20× using a 3-kDa Amicon Ultra-15 Centrifugal Filter Unit (Millipore Sigma, UFC900324) before use. The cells were collected for flow cytometry analysis.

**Mice immunization and sample collection**

Antigens encoded by the mRNA vaccines were derived from SARS-CoV-2 isolate Wuhan-Hu-1 (GenBank MN908947.3). Nucleoside-modified mRNAs encoding the full length of the Spike protein from SARS-CoV-2 with two proline mutations (mRNA-S) were synthesized by in vitro transcription using T7 RNA polymerase (Megascript, Ambion) as previously reported (55). mRNAs were formulated into lipid nanoparticles (LNPs) using an ethanolic lipid mixture of ionicizable cationic lipid and an aqueous buffer system as previously reported (56). Formulated mRNA-LNPs were prepared according to RNA concentrations (~1 μg/μl) and were stored at ~80°C for animal immunizations. All animal protocols were approved by the Institutional Animal Care and Use Committees of the Mayo Clinic (Rochester, MN, #A00002035) or the University of Virginia (Charlottesville, VA, #4369). Eight- to 10-week-old female C57BL/6 mice (the Jackson Laboratory, 000664) were vaccinated with one or two doses of 1 μg of mRNA-S with a 21-day interval. Another 21 days later, mice were boosted with PBS, 1 μg of mRNA-S intramuscularly, 3 μg of S-trimer (Sino Biological, 40589-V08H8) adjuvanted with 10 μg of 2′3′-cGAMP (Invivogen, tlrl-nacga23) intranasally, or 10^9 plaque-forming units (PFU) of Ad5-S (University of Iowa Viral Vector Core) intranasally after being anesthetized by intraperitoneal injection of ketamine and xylazine. The volume of intranasal administrations was 30 μl. Three doses of PBS-administered mice were used as control. Fourteen days later, mice were euthanized. BAL, blood, and splenocytes were collected for analysis. Isolated plasma inactivated for 30 min at 56°C, supernatant of the first 600 μl (for two doses of mRNA plus a third intranasal immunization) or 1.6 ml (for one dose of mRNA plus a second intranasal immunization), and 1 ml of nasal wash were collected and stored at −80°C for ELISA or neutralization assay. The cells were collected for flow cytometry analysis. Influenza A/PR8/34 (200 PFU) was used to infect mice intranasally. At day 6 after infection, the left lobe of the lung was subjected for histopathology.

**Binding antibody response against SARS-CoV-2**

The general ELISA method has been previously described (19). Briefly, recombinant SARS-CoV-2 proteins including RBD (Sino Biological, 40592-V08H1), spike S1 D614G (S1) (Sino Biological, 40591-V08H3), spike S1 + S2 ectodomain (ECD) (S) (Sino Biological, 40589-V08H4), or nucleocapsid protein (N) (GenScript, Z03488) were precoated to 96-well plates overnight at 4°C. The next day, plates were washed with wash buffer (0.05% Tween 20 in PBS) and then blocked with assay dilution buffer (BioLegend, 421203) for 1 hour at RT. Plasma or 20× concentrated BAL from unvaccinated donors, vaccinated individuals, and convalescents were diluted in “assay dilution buffer” starting at a 1:5 or 1:1 dilution, respectively, and then serially diluted by a factor of 5. Plasma from mice were diluted starting at 1:100 dilution and then serially diluted by a factor of 5. BAL from mice was not concentrated or diluted. Samples were added to the plate and incubated for 2 hours at RT. After washing three times with wash buffer, secondary antibodies diluted with assay dilution buffer were added to the plate and then incubated for 1 hour at RT. Secondary antibodies, including anti-human IgG (Sigma-Aldrich, A6029), anti-human IgA (Hybridoma Reagent Laboratory, HP6123), anti-IgM (Sigma-Aldrich, A6907), anti-mouse IgG (SouthernBiotech, 1030-05), anti-mouse IgA (SouthernBiotech, 1040-05), and anti-mouse IgM (SouthernBiotech, 1020-05) were diluted as respectively indicated. Plates were washed three times and then developed with 3,3′,5,5′-tetramethyl benzidine buffer (Thermo Fisher Scientific, 00-4201-56) for 10 min at RT. Sulfuric acid (2 M) was used as STOP buffer. Plates were read at about 5 min on a microplate.
reader (Molecular Devices) at 450 nm with SoftMax Pro Software. The optical density value at 1:5 dilution for human plasma, 1:1 dilution for human BAL, 1:100 for mice plasma (1:500 for IgG), or original mice BAL and nasal wash was displayed, respectively; one dot represents each individual.

Neutralizing antibody response against SARS-CoV-2

Pseudovirus neutralization assays were performed as previously reported (57). Briefly, in a 96-well format, plasma or BAL was diluted starting at a 1:40 or 1:20 dilution, respectively, and then serially diluted by a factor of 4. The pseudoviruses, including D614G, Delta (B.1.617.2), and Omicron BA.1.1, were incubated with plasma or BAL for 1 hour at 37°C, followed by infection of 2 × 10⁴ preseeded human embryonic kidney (HEK) 293T–ACE2 cells [Biodense and Emerging Infections Research Resources Repository (BEI Resources, NR-52511)] on a 96-well polystyrene tissue culture plate. Gaussia luciferase activity in cell culture media was assayed 48 and 72 hours after infection. Note that, to ensure valid comparisons between SARS-CoV-2 variants, we used equivalent amounts of pseudovirus on the basis of the predetermined virus titers, and samples of different SARS-CoV-2 variants were loaded side by side in each plate. NT₅₀ for each sample was determined by nonlinear regression with least squares fit in GraphPad Prism 5 (GraphPad Software).

Flow cytometry analysis

Fresh mice and human cells or frozen human PBMCs or BAL cells recovered and rested overnight in a 37°C, 5% CO₂ incubator was washed with fluorescence-activated cell sorting (FACS) buffer [1% fetal bovine serum (FBS) and 0.5 M EDTA in PBS] and then stained with antibodies as listed in table S2 for humans and table S3 for mice. Intracellular cytokine staining was performed to detect vaccine-specific T cell response. Briefly, cells were washed with FACS buffer and resuspended with complete RPMI 1640 with 10 mM Hepes supplemented with 10% FBS, 2-mercaptoethanol, sodium pyruvate, non-essential amino acids, penicillin-streptomycin, and 1-glutamine. Cells were then stimulated with 5 peptide pool (1 μg/ml; JPT, PM-WCPV-S) for stimulation for 6 hours (PBMC for 16 hours). In the last 4 hours of incubation, protein transport inhibitor brefeldin A was added. Cells stimulated with phorbol 12-myristate 13-acetate/ionomycin or dimethyl sulfoxide (DMSO) only were included as positive control and negative control, respectively. After stimulation, cells were first stained for surface markers on ice for 30 min. After washing with PBS, cells were resuspended with Zombie dye for viability staining and incubated at RT for 15 min. After surface and viability staining, cells were fixed with fixation buffer (BioLegend, 420801) and permeabilized with Perm/Wash buffer (BioLegend, 421002), followed by intracellular cytokine staining on ice for 30 min. Cells were then washed with Perm/Wash buffer and resuspended with FACS buffer. To detect RBD-specific B cells, we incubated recombinant RBD proteins coupled with phycoerythrin (PE) and allophycocyanin (APC) with the cells for 30 min at 4°C. RBD-PE and RBD-APC double-positive B cells were identified as RBD⁺ B cells. To detect S₃₉₉–₅₄₆ epitope–specific CD8⁺ T cells, we incubated SARS-CoV-2 S₃₅₉–₅₄₆ major histocompatibility complex class I tetramer (H-2Kb) [National Institutes of Health (NIH) Tetramer Core] with the cells for 30 min at 4°C. CD44⁺ tetramer–positive CD8⁺ T cells were identified as S₃₅₉–₅₄₆ epitope–specific CD8⁺ T cells. Cell population data were acquired on a multispectral flow cytometer Cytek Aurora (Cytek Biosciences) or Attune NxT (Thermo Fisher Scientific) and analyzed using FlowJo Software (10.8.1, Tree Star Inc.). All human data from cytokine production assays were background-subtracted using paired DMSO-treated control samples.

Histopathology

At 6 days after infection with Ad5-S or PR8, the left lobe of the whole lung from each mouse was harvested and fixed in formalin (Thermo Fisher Scientific) until embedding. Fixed lung tissues were embedded in paraffin. Lung tissue slides were stained with hematoxylin and eosin by the University of Virginia Research Histology Core (Charlottesville, VA) and scanned by the University of Virginia Biorepository and Tissue Research Facility (Charlottesville, VA).

Statistical analysis

Statistical tests are indicated in the corresponding figure legends. One-way analysis of variance (ANOVA) was used in multigroup comparison. Paired t test was used in PBMC and BAL paired comparison. Others were analyzed using independent t test. All tests were performed with a nominal significance threshold of P < 0.05, which is displayed by a single asterisk. P > 0.05 was displayed by ns, which means not significant. Two asterisks indicate P < 0.01, three asterisks indicate P < 0.001, and four asterisks indicate P < 0.0001.

SUPPLEMENTARY MATERIALS

www.science.org/doi/10.1126/sciimmunol.add4853

Figs: S1 to S9

Tables S1 to S4

View/request a protocol for this paper from Bio-protocol.

REFERENCES AND NOTES

1. F. Krammer, SARS-CoV-2 vaccines in development. Nature 586, 516–527 (2020).
2. T. Carvalho, F. Krammer, A. Iwasaki, The first 12 months of COVID-19: A timeline of immunological insights. Nat. Rev. Immunol. 21, 245–256 (2021).
3. M. Sadarangan, A. Marchant, T. R. Kollmann, Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat. Rev. Immunol. 21, 475–484 (2021).
4. R. K. Gupta, E. J. Topol, COVID-19 vaccine breakthrough infections. Science 374, 1561–1562 (2021).
5. K. J. Siddle, L. A. Krasilnikova, G. K. Moreno, S. F. Schaffner, J. Vostok, N. A. Fitzgerald, J. E. Lemieux, N. Barkas, C. Lorent, I. Specht, C. H. Tomkins-Tinch, J. S. Paul, B. Scheaffer, B. P. Taylor, B. Loftness, H. Johnson, P. L. Schubert, H. M. Shephard, M. Doucette, T. Fink, A. S. Lang, S. Baez, J. Beauchamp, S. Hennigan, E. Busby, S. Ash, J. Brown, S. Clancy, S. Cofsky, L. Gagne, J. Hall, R. Harrington, G. L. Gionet, K. C. DeRuff, M. E. Vodzak, G. C. Adams, S. T. Dobbins, S. D. Slack, S. K. Reilly, L. M. Anderson, M. C. Cipicchio, M. T. DeFelice, J. L. Grimsby, S. E. Anderson, B. S. Blumenstiel, J. C. Meldrim, H. M. Rooke, G. Vicente, N. L. Smith, K. S. Messer, F. L. Reagan, Z. M. Mandese, M. D. Lee, M. C. Ray, M. E. Fisher, M. A. Ulcena, C. M. Nolet, S. E. English, K. L. Larkin, K. Vernet, S. Chaluvadi, A. Arvidson, M. Melchion, T. Covell, H. Harik, T. Brock-Fisher, M. Dunn, A. Kearns, W. P. Hanage, C. Bernard, A. Philippakis, N. J. Lennon, S. B. Gabriel, G. R. Gallagher, S. Smole, L. C. Madoff, C. M. Brown, D. J. Park, B. M. Almquist, P. C. Sabeti, Transmission from vaccinated individuals in a large SARS-CoV-2 Delta variant outbreak. Cell 185, 485–492.e10 (2021).
6. J. S. Tregoning, K. E. Flight, S. L. Higham, Z. Wang, B. F. Pioneer, The progress of the COVID-19 vaccine effort: Viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat. Rev. Immunol. 21, 626–636 (2021).
7. A. Iwasaki, Exploiting mucosal immunity for antiviral vaccines. Annu. Rev. Immunol. 34, 575–608 (2016).
8. L. Liu, S. Itkoni, Y. Guo, J. F. Wh Chan, M. Wang, L. Liu, Y. Luo, H. Chu, Y. Huang, M. S. Nair, J. Yu, K. K. H. Chik, T. T. T. Yuen, C. Yoon, K. K. W. To, H. Chen, M. T. Yin, M. E. Sobieszczyk, Y. Huang, H. H. Wang, Z. Sheng, K.-Y. Yuen, D. D. Ho, Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 602, 676–681 (2022).
9. J. M. Carreño, H. Alshammary, J. Tcheou, G. Singh, A. Raskin, H. Kawabata, L. Sominsky, A. Paniz-Mondolfi, J. Polanco, K. Srivastava, D. N. Sather, E. M. Sordillo, G. Bajic, A. Cognigni, K. Farrugia, C. Gleason, A. van de Guchte, G. Kleiner, Z. Khalil, N. Lyttle, W. P. Hanage, C. Bernard, A. Philippakis, N. J. Lennon, S. B. Gabriel, G. R. Gallagher, S. Smole, L. C. Madoff, C. M. Brown, D. J. Park, B. M. Almquist, P. C. Sabeti, Transmission from vaccinated individuals in a large SARS-CoV-2 Delta variant outbreak. Cell 185, 485–492.e10 (2021).
A. Ssemaganda, H. M. Nguyen, F. Nuhu, N. Jahan, C. M. Card, S. Kiazyk, G. Severini, J. M. Er Lim, A. T. Tan, N. Le Bert, S. K. Hang, J. G. Hong Low, A. Bertoletti, SARS-CoV-2 Z. Wang, F. Schmidt, Y. Weisblum, F. Muecksch, C. O. Barnes, S. Finkin, D. Schaefer-Babajew, H. van Bakel, V. Simon, F. Krammer, Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron to antibody neutralization. Nature 602, 671–675 (2022).

C. O. Barnes, S. Finkin, D. Schaefer-Babajew, H. van Bakel, V. Simon, F. Krammer, Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron to antibody neutralization. Nature 602, 671–675 (2022).

A. Mui, B. G. Lui, A.-K. Wallisch, M. Bacher, J. Mühl, J. Reinholz, O. Ozhelvaci, N. Beckmann, R. de la Caridad Guimil Garcia, A. Poran, S. Shpyro, A. Finlayson, H. Cai, R. J. Lessells, M.-Y. S. Moosa, M. P. Davenport, T. de Oliveira, P. L. Moore, A. Sigal, Omicron W.-H. Bolland, F. Porrot, I. Staropoli, F. Lemoine, H. Péré, D. Veyer, J. Puech, J. Rodary, R. E. Salomon-Shulman, G. Blacker, M. Fazel-Zarandi, B. Rathod, K. Colwill, A. Jamal, Z. Li, A. McGeer, G. Regev-Yochay, S. Straus, A.-C. Gingras, J. L. Gommerman, Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection. medRxiv 21621267 (2022). https://doi.org/10.1101/2022.01.21.21261297.

M. Stolovich-Rain, S. Kumar, A. Friedman, S. Kriroil, Y. Socol, M. Billan, R. R. Pal, P. Goldberg, E. Okinine-Dijane, S. Sirhan, M. B. Sagie, E. Cohen-Kfir, M. Elgrably-Weiss, B. Zou, M. Ravins, Y. E. Gatt, K. Das, O. Zelig, R. Wiener, D. G. Holf, E. Hlinav, J. Strahlievitz, D. Padawar, L. Baraz, A. Rouvinvski, Intra muscular mRNA BNT162b2 vaccine against SARS-CoV-2 induces robust neutralizing salivary IgA bioRxiv 480851 [Preprint]. 17 February 2022. https://doi.org/10.1101/2022.02.17.480851.

W. Garcia-Beltran, K. J. S. Denis, A. Hoelzemer, E. C. Lam, A. D. Nilitto, M. L. Sheehan, C. Berrios, O. Ofoman, C. C. Chang, M. B. Hauser, J. Feldman, A. L. Roederer, D. J. Gregory, M. C. Poznansky, A. G. Schmidt, A. J. Lafarte, V. Naranbhani, A. B. Balazs, mRNA-based COVID-19 vaccine induces neutralizing immunity against SARS-CoV-2 Omicron variant. Cell 185, 457–466.e4 (2022).

L. Liu, P. Wang, M. S. Nair, J. Yu, M. Rapp, Q. Wang, Y. Luo, J. F. Chan, V. Sahi, A. Figueroa, X. Y. Guo, C. Gerutti, J. Bimela, J. Gorman, T. Zhou, Z. Chen, K. Y. Yuen, P. D. Kwong, J. G. Sosdioski, M. T. Yin, Z. Sheng, Y. Huang, L. Shapiro, D. D. Ho, Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584, 450–456 (2020).

D. Cromer, M. Stein, A. Reynaldi, T. E. Schlub, A. K. Wheatley, A. J. Juno, S. J. Kent, J. A. Tricas, D. S. Khoury, M. P. Davenport, Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: A meta-analysis. Lancet Microbe 3, e52–e51 (2022).

S. D. Khoury, D. Cromer, A. Reynolds, T. E. Schlub, A. K. Wheatley, A. J. Juno, K. Subbarao, S. M. Rajah, A. J. Tricas, M. P. Davenport, Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205–1211 (2021).

C. Liu, H. M. Ginn, W. Deijnrijk, P. Supasa, B. Wang, A. Tukeprakhun, N. Rutalai, D. Zhou, A. J. Mentzer, Y. Zhao, H. M. E. Duveyestyn, C. Lopez-Camacho, J. Slon-Campos, T. W. S. Dickey, S. J. Johnson, T. G. Ritter, C. Mason, S. A. C. Clemens, G. F. Naveca, V. Nascimento, F. Nascimento, C. F. da Costa, P. C. Concede, A. Pauvolid-Correia, M. M. Siqueira, C. Dold, N. Temperton, T. Dong, A. J. Pollard, J. C. Knight, D. Crook, T. Lambe, E. Clutterbuck, S. Bibi, A. Flaxman, M. Bittaye, S. Belji-Rammerstorfer, S. C. Gilbert, T. Malik, M. W. Carroll, P. Klenner, E. Barnes, S. J. Dunachie, V. Banille, N. Serafin, Z. Ditse, K. Da Silva, N. G. Paterson, M. A. Williams, D. R. Hall, S. Madhi, M. C. Nunes, P. Goulder, E. E. F. Ery, J. Mongkolpapaya, J. Ren, D. J. Stuart, G. R. Sceraton, Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent cell. Sci. Immunol. 184, 4220–4236.e13 (2021).

D. Plansa, D. Veyer, A. Baidaliak, I. Staropoli, F. Guivel-Benhasse, M. M. Rajah, C. Planchais, F. Porrot, N. Robillard, J. Puech, M. Prot, F. Gallant, P. Avelar, A. Velay, J. A. Tricas, M. P. Davenport, Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205–1211 (2021).

M. Siqueira, C. Dold, N. Temperton, T. Dong, A. J. Pollard, J. C. Knight, D. Crook, T. Lambe, E. Clutterbuck, S. Bibi, A. Flaxman, M. Bittaye, S. Belji-Rammerstorfer, S. C. Gilbert, T. Malik, M. W. Carroll, P. Klenner, E. Barnes, S. J. Dunachie, V. Banille, N. Serafin, Z. Ditse, K. Da Silva, N. G. Paterson, M. A. Williams, D. R. Hall, S. Madhi, M. C. Nunes, P. Goulder, E. E. F. Ery, J. Mongkolpapaya, J. Ren, D. J. Stuart, G. R. Sceraton, Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent cell. Sci. Immunol. 184, 4220–4236.e13 (2021).

H. van Bakel, V. Simon, F. Krammer, Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature 602, 682–688 (2022).

D. Planas, N. Saunders, P. Maes, F. Guivel-Benhasse, C. Planchais, J. Buchrieser, W.-H. Bolland, F. Porrot, I. Staropoli, F. Lemoine, H. Péret, D. Veyer, J. Puech, J. Rodary, G. Baêle, S. Delllouir, J. Payenmant, S. Gorrissant, G. M. C. Hoffmann, Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection. medRxiv 21621267 (2022). https://doi.org/10.1101/2022.01.21.21261297.

M. Stolovich-Rain, S. Kumar, A. Friedman, S. Kriroil, Y. Socol, M. Billan, R. R. Pal, P. Goldberg, E. Okinine-Dijane, S. Sirhan, M. B. Sagie, E. Cohen-Kfir, M. Elgrably-Weiss, B. Zou, M. Ravins, Y. E. Gatt, K. Das, O. Zelig, R. Wiener, D. G. Holf, E. Hlinav, J. Strahlievitz, D. Padawar, L. Baraz, A. Rouvinvski, Intra muscular mRNA BNT162b2 vaccine against SARS-CoV-2 induces robust neutralizing salivary IgA bioRxiv 480851 [Preprint]. 17 February 2022. https://doi.org/10.1101/2022.02.17.480851.

W. Garcia-Beltran, K. J. S. Denis, A. Hoelzemer, E. C. Lam, A. D. Nilitto, M. L. Sheehan, C. Berrios, O. Ofoman, C. C. Chang, M. B. Hauser, J. Feldman, A. L. Roederer, D. J. Gregory, M. C. Poznansky, A. G. Schmidt, A. J. Lafarte, V. Naranbhani, A. B. Balazs, mRNA-based COVID-19 vaccine induces neutralizing immunity against SARS-CoV-2 Omicron variant. Cell 185, 457–466.e4 (2022).
39. M. M. Painter, D. Mathew, R. R. Goel, S. A. Apostolidis, A. Pattekar, O. Kuthuru, A. E. Baxter, R. S. Herati, D. A. Oldridge, S. Gouma, P. Hicks, S. Dysinger, K. A. Lundgreen, L. Kuri-Cervantes, S. Adamski, A. Hicks, S. Korte, J. R. Giles, M. E. Weirick, C. M. McAllister, J. Dougherty, S. Long, K. D’Andrea, J. T. Hamilton, M. R. Bettis, P. Bates, S. E. Hensley, A. Girifoni, D. Weiskopf, A. Sette, A. R. Greenplate, E. J. Wherry, Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. *Immunity* 54, 2133–2142.e3 (2021).

40. A. Abbassler, Z. J. Chen, cGAS in action: Expanding roles in immunity and inflammation. *Science* 363, eaat8657 (2019).

41. F. E. Lund, T. D. Randall, Scent of a vaccine. *Science* 373, 397–399 (2021).

42. T. M. Leon, V. Dorabawila, L. Nelson, E. Lutterloh, U. E. Bauer, B. Backenson, M. T. Bassett, Y. Goldberg, M. Mandel, Y. M. Bar-On, O. Bodenheimer, L. S. Freedman, N. Ash, J. Sun, T. J. Braciale, Role of T cell immunity in recovery from influenza virus infection. *JCI Insight* 5, e143213 (2020).

43. A. D. Redd, A. Nardin, H. Kared, E. M. Bloch, B. Abel, A. Pekosz, O. Laeyendecker, S. J. Choi, D.-U. Kim, J. Y. Noh, S. Kim, S.-H. Park, H. W. Jeong, E.-C. Shin, T cell epitopes of SARS-CoV-2 Delta variant on incubation, vaccination settings and vaccine effectiveness: Results from a nationwide case-control study in France. *Lancet Respir. Med.* 13, 100278 (2022).

44. Y. Goldberg, M. Mandel, Y. M. Bar-On, O. Bodenheimer, L. S. Freedman, N. Ash, S. Aroy-Preis, A. Huppert, R. Milo, Protection and waning of natural and hybrid immunity to SARS-CoV-2. *N. Engl. J. Med.* 386, 2201–2212 (2022).

45. J. Sun, T. J. Braciale, Role of T cell immunity in recovery from influenza virus infection. *Curr. Opin. Virol.* 3, 425–429 (2013).

46. A. Tarke, C. H. Coelho, Z. Zhang, J. M. Dan, E. D. Yu, N. Methot, N. I. Bloom, B. Goodwin, Y. Adachi, T. Onodera, Y. Yamada, R. Daio, M. Tsuiji, T. Inoue, K. Kobayashi, T. Kurosaki, S. Alroy-Preis, A. Huppert, R. Milo, Protection and waning of natural and hybrid immunity to SARS-CoV-2. *Cell. Mol. Immunol.* 19, 847–859.e11 (2022).

47. S. J. Choi, D.-U. Kim, J. Y. Noh, S. Kim, S.-H. Park, H. W. Jeong, E.-C. Shin, T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant. *Cell Mol. Immunol.* 19, 447–448 (2022).

48. A. Terke, C. H. Coelho, Z. Zhang, J. M. Dan, E. D. Yu, N. Methot, N. I. Bloom, B. Goodwin, E. Phillips, S. Malal, J. Sidney, G. Filaci, D. Weiskopf, R. da Silva Antunes, S. Crotty, A. Girifoni, A. Sette, SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. *Cell* 185, 847–859.e11 (2022).

49. S. Wu, J. Huang, Z. Zhang, J. Wu, J. Zhang, H. Hu, T. Zhu, J. Zhang, L. Luo, P. Fan, B. Wang, C. Chen, Y. Chen, X. Song, Y. Wang, W. Si, T. Sun, X. Wang, L. Hou, W. Chen, Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5s-nCoV) in adults: Preliminary report of an open-label and randomised phase 1 clinical trial. *Lancet Infect. Dis.* 21, 1654–1664 (2021).

50. S. Iyer, R. Yadav, S. Agarwal, S. Tripathi, R. Agarwal, Bioengineering strategies for developing vaccines against respiratory viral diseases. *Clin. Microbiol. Rev.* 35, e0012321 (2022).

51. Y. Adachi, T. Ohto, Y. Yamada, R. Daio, M. Tsuiji, T. Inoue, K. Kobayashi, T. Kurosaki, A. Tarke, C. H. Coelho, Z. Zhang, J. M. Dan, E. D. Yu, N. Methot, N. I. Bloom, B. Goodwin, Y. Adachi, T. Onodera, Y. Yamada, R. Daio, M. Tsuiji, T. Inoue, K. Kobayashi, T. Kurosaki, S. Alroy-Preis, A. Huppert, R. Milo, Protection and waning of natural and hybrid immunity to SARS-CoV-2. *Cell. Mol. Immunol.* 19, 847–859.e11 (2022).

52. N. Swarnalekha, D. Schreiner, L. C. Litzler, S. Iftikhar, D. Kirchmeier, M. Kunzli, Y. M. Son, J. Sun, E. M. Moreira, C. G. King, T resident helper cells promote humoral responses in the lung. *Sci. Immunol.* 6, eabb6808 (2021).

53. E. Kowarz, L. Kutzke, M. Kulip, P. Streb, P. Larghero, J. Reis, S. Bracharz, T. Engler, S. Kochanek, R. Marschalek, Vaccine-induced COVID-19 mimicry syndrome. *Sci. Immunol.* 6, e74974 (2022).

54. D. L. Farber, Tissues, not blood, are where immune cells function. *Nature* 593, 506–509 (2021).

55. N. Pardi, H. Muramatsu, D. Weissman, K. Karkio, In vitro transcription of long RNA containing modified nucleosides. *Methods Mol. Biol.* 969, 29–42 (2013).

56. M. A. Maier, M. Jayaraman, S. Matsuda, J. Liu, S. Barros, W. Querbes, Y. K. Yam, S. M. Ansell, V. Kumar, J. Qin, X. Zhang, Q. Wang, S. Panesar, R. Hutabarat, M. Canioto, J. Hettinger, P. Kandasamy, D. Butler, K. G. Rajeev, B. Pang, K. Charisse, K. Fitzgerald, B. L. Mui, X. Du, P. Cullis, T. D. Maddern, M. J. Hope, M. Manoharan, A. Akinc, Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNA therapeutics. *Mol. Ther.* 21, 1570–1578 (2013).

57. C. Zeng, J. P. Evans, R. Pearson, P. Qu, Y. M. Zheng, R. T. Robinson, L. Hall-Stoodley, J. Yount, S. Pannu, R. K. Mallampalli, L. Saif, E. Oltz, G. Lozanski, S. L. Liu, Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors. *JCI Insight* 5, e143213 (2020).

Acknowledgments: We thank the study participants for contribution to this work. We thank B. Zhu, X. Wei, M. Arish, R. Zhang, N. Harish, and W. Qian for the experimental assistance. Funding: This study is partially funded by the U.S. NIH grants AI147394, AG047156, and AG069264 to J.S. and AI14739451 to J.S. and R.V. The work in the Liu laboratory was supported by a fund provided by an anonymous private donor to Ohio State University and NCI U54CA260582 to S.-L.L. The content is solely the authors’ responsibility and does not necessarily represent the official views of the NIH. M.H.K. was supported by AI057459. H.H. was supported by AI47903 and AI517582. Author contributions: J.T., S.-L.L., and J.S. conceptualized the study. J.T., C.Z., C.L., Y.M.S., I.S.C., and Y.W. performed experiments. J.T. and C.Z. analyzed and interpreted the data. T.M.C. and S.B. conducted the recruitment of participants. R.C., D.N.S., J.P.U., J.S.R., D.E.M., J.J.M., E.S.E., and R.K. collected the clinical samples. J.T.T., A.J.J., M.G.A. D.W., and H.H. provided experimental materials. J.T. and J.S. wrote the initial draft. C.Z. and S.-L.L. edited the draft, L.B., W.G.T., M.H.K., and R.V. reviewed the draft. All authors contributed to the final draft. Competing interests: J.S. is a consultant for the Teneofoor company, which is not directly involved with this project. All other authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper or the Supplementary Materials. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material.

Submitted 14 June 2022
Accepted 11 July 2022
Published First Release 19 July 2022
Final published 21 October 2022
10.1126/sciimmunol.add4853